Cannabis Stock News: Nextleaf (CSE: OILS) Awarded Jamaican Patent For Its Foundational Extraction Process


(MENAFN- Investor Ideas)

-->
Cannabis Stock News: Nextleaf (CSE: OILS) Awarded Jamaican Patent for its Foundational Extraction Process

 

Vancouver, British Columbia - May 25, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ('Nextleaf' or the 'Company'), a federally regulated manufacturer and distributor of cannabis vapes and oils, announced today the Jamaica Intellectual Property Office has granted Nextleaf a patent for the Company's foundational process for producing high-purity CBD and THC ingredients.

Nextleaf's patented technology allows for oil-grade cannabis and hemp flower to be efficiently processed into a high-purity distilled cannabinoids. The resulting THC or CBD distillate is tasteless, odourless, standardized for potency, and ready to use as the hero ingredient in a wide range of products, including vapes, oils, softgels, transdermal or sublingual delivery, and water-soluble extracts.




The Company has been issued 18 U.S. patents, and over 95 patents globally, on cannabinoid processing including extraction, distillation, and acetylation. Nextleaf initially files its patents in the United States to create a priority date and allow for future filings in other selected jurisdictions. This is common in the field of intellectual property ('IP') protection. The Company owns issued patents in the United States, Canada, Mexico, Israel, Germany, Australia, Colombia, South Africa, the U.K., and across Europe. Nextleaf follows a global IP strategy of protecting the means to producing standardized cannabinoid-based products at scale within a regulated market.

Medical cannabis is currently legal in Jamaica and possession of small amounts of marijuana was decriminalized in 2015, with residents permitted to grow up to five plants for personal use only.

'This patent reinforces our vision of developing intellectual property that improves cannabis oil economics globally,' said Paul Pedersen, CEO of Nextleaf Solutions. 'We believe there will be a regulated commercial market for cannabinoid-based products in Jamaica during the 20-year life of this patent'.

Nextleaf Issues Warrants

The Company has issued 500,000 warrants to purchase common shares of the Company to the holder of the convertible note issued on March 31, 2021 (the 'Note'). The warrants were issued as consideration for revision of terms of the Note and are exercisable at a price of $0.138 per share for a period of 36 months from the date of issuance.

About Nextleaf Solutions Ltd.

Nextleaf® is a federally regulated manufacturer and distributor of cannabis vapes and oils under its award-winning prohibition-era brand, Glacial Gold™. The Company's multi-patented ingredient processing technology transforms cannabis and hemp biomass into high-purity distillate at an industrial scale. Nextleaf is a low-cost producer of cannabis oils, and supplier of THC and CBD ingredients to qualified wholesale partners across Canada. Nextleaf is the first publicly traded company to be issued a U.S. patent for the industrial extraction and purification of cannabinoids. The Company has been issued 18 U.S. patents, and over 95 patents globally, on cannabinoid processing including distillation and acetylation. Nextleaf develops cannabinoid-based formulations and delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. For more information visit and

Nextleaf trades as OILS on the Canadian Securities Exchange , OILFF on the OTCQB Market in the United States , and L0MA on the Frankfurt Stock Exchange .

Follow the Company: Twitter , LinkedIn , Facebook , and Instagram .

Follow Glacial Gold™: Instagram , Twitter , and Facebook .

Jason McBride, Corporate Development
604-283-2301 (ext. 219)

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute 'forward-looking statements' within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the Company's intellectual property('IP'), expected IP licensing revenues, and those regarding the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words 'believe', 'expect', 'aim', 'intend', 'plan', 'continue', 'will', 'may', 'would', 'anticipate', 'estimate', 'forecast', 'predict', 'project', 'seek', 'should' or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the Investorideas.com newswire and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:




Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks Buy a cannabis guest post on Investorideas.com



About Investorideas.com

Sign up for free stock news alerts at Investorideas.com




MENAFN29052022000142011025ID1104288612


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.